Shih-Han Kao

794 citations
22 papers · 595 indexed · h-index 12
Topics
Heme Oxygenase-1 and Carbon Monoxide (4 papers)Ubiquitin and proteasome pathways (4 papers)Traumatic Brain Injury and Neurovascular Disturbances (4 papers)

In The Last Decade

Shih-Han Kao

20 papers receiving 592 citations

Peers

Shih-Han Kao
Comparison fields: 5 of 85
  • Molecular Biology 419
  • Cancer Research 152
  • Oncology 112
  • Biomedical Engineering 82
  • Pulmonary and Respiratory Medicine 70
Replace Ling Xi with:
Ling Xi China
Ruth M. Escalona Australia
Xiaoxiao Huang China
Ryou Takahashi Japan
Ana R. Rama Spain
Detian Yuan China
Hengliang Shi China
Xiaobing Tian United States
Ebrahim Kharazinejad Iran
Zhengwei Leng China
Shih-Han Kao relative to Ling Xi China Ling Xi's profile →
Citations per field
00.5×1.6×
Ling Xi · 1×
Citations per year

Countries citing papers authored by Shih-Han Kao

Since Specialization
Citations

This map shows the geographic impact of Shih-Han Kao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shih-Han Kao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shih-Han Kao more than expected).

Fields of papers citing papers by Shih-Han Kao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shih-Han Kao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shih-Han Kao. The network helps show where Shih-Han Kao may publish in the future.

Co-authorship network of co-authors of Shih-Han Kao

This figure shows the co-authorship network connecting the top 25 collaborators of Shih-Han Kao. A scholar is included among the top collaborators of Shih-Han Kao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shih-Han Kao. Shih-Han Kao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 2
4 4
5 5
6 25
7 3
8 6
9 7
10 20
11 80
12 46
13 37
14 18
15 86
16 96
17 14
18 66
19 3
20
An adaptive power-line interference removal technique for biopotential measurement
2

About Shih-Han Kao

Shih-Han Kao is a scholar working on Neurology, Emergency Medicine and Clinical Biochemistry, having authored 22 papers that have together received 595 indexed citations. Recurring topics across this work include Heme Oxygenase-1 and Carbon Monoxide (4 papers), Ubiquitin and proteasome pathways (4 papers) and Traumatic Brain Injury and Neurovascular Disturbances (4 papers). The work is most often cited by research in Cancer Research (152 citations), Molecular Biology (419 citations) and Oncology (112 citations). Shih-Han Kao has collaborated with scholars based in Taiwan, United States and Sweden. Frequent co-authors include Kou‐Juey Wu, Pan‐Chyr Yang, Han‐Tsang Wu, Tse‐Ming Hong, Kuo‐Yen Huang, Shuenn‐Chen Yang, Wen‐Hwa Lee, Yu‐Ju Chen, Yi‐Ting Wang and Zi‐Xian Liao. Their work appears in journals such as Nature Communications, ACS Nano and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026